Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy
Open accessThe DOI matches its Crossref record; 114 of the 115 references it cites were found in a registry or an index; 21 of the 126 sources its claims cite were checked for support.
Abstract
Inherited retinal diseases (IRDs) are a leading cause of blindness in industrialized countries, and gene therapy is quickly becoming a viable option to treat this group of diseases. Gene replacement using a viral vector has been successfully applied and advanced to commercial use for a rare group of diseases. This, and the advances in gene editing, are paving the way for the emergence of a new generation of therapies that use CRISPR–Cas9 to edit mutated genes in situ. These CRISPR-based agents can be delivered to the retina as transgenes in a viral vector, unpackaged transgenes or as proteins or messenger RNA using non-viral vectors. Although the eye is considered to be an immune-privileged organ, studies in animals, as well as evidence from clinics, have concluded that ocular gene therapies elicit an immune response that can under certain circumstances result in inflammation. In this review, we evaluate studies that have reported on pre-existing immunity, and discuss both innate and adaptive immune responses with a specific focus on immune responses to gene editing, both with non-viral and viral delivery in the ocular space. Lastly, we discuss approaches to prevent and manage the immune responses to ensure safe and efficient gene editing in the retina.
Overview
CoChat Summary
TL;DR
This narrative review examines pre-existing and post-treatment innate and adaptive immune responses to retinal gene therapy, covering viral vectors (AAV, lentivirus, adenovirus), non-viral delivery (naked DNA, lipoplexes, polymers, nanoparticles, VLPs), and CRISPR-Cas9 components. It argues that the eye's immune privilege is not absolute and surveys vector-oriented and immune-response-oriented strategies to prevent or manage these responses.
Key findings
- Pre-existing immunity to Cas9 is common: in 125 healthy US adult blood donors (median age 43), anti-SaCas9 and anti-SpCas9 antibodies were found in 78% and 58% respectively; 78% had SaCas9-specific T-cells and 67% SpCas9-specific T-cells. A canine study found anti-SpCas9 antibodies in all 78 adult animals but not in 16 newborns.
- Pre-existing anti-AAV seroprevalence is high and serotype-dependent: in 226 healthy donors, serum IgG prevalence was AAV2 72%, AAV1 67%, AAV9 47%, AAV6 46%, AAV5 40%, AAV8 38%; in 888 serum samples across 10 countries, AAV2 was highest and the novel variant AAVrh32.33 lowest.
- Clinical ocular gene therapy trials report inflammation: in NCT00999609 (Phase 3), mild inflammation in 2 of 21 patients; in NCT02781480 (Phase 1/2), uveitis in 1/3 low-dose, 3/3 intermediate-dose and 2/3 high-dose patients; in an AMD Ad trial, 25% of 28 patients developed transient intraocular inflammation; in a retinoblastoma cohort, 5 of 8 patients developed ocular inflammation without measurable humoral or cellular response.
- Non-viral vectors are not necessarily less immunogenic: chitosan induced inflammatory cell infiltration and retinal degeneration in rabbits, while gold nanoparticles reduced LPS-induced inflammation via the TLR4-NFκB pathway; VLP-mediated base editing reached >95% efficiency in fibroblasts, 53–55% in mouse CNS, 63% in liver, and 21% in RPE with visual rescue in rd12 mice.
Methods
- Narrative review; no experimental data were generated or presented (stated explicitly in the Institutional Review Board, Data Availability, and Additional Information statements).
- Synthesizes published human, non-human primate, canine, rodent and in vitro studies on pre-existing immunity, innate and adaptive responses to viral and non-viral ocular delivery, and immunosuppressive strategies.
- No systematic search protocol, inclusion criteria, or quantitative synthesis is described.
Limitations
- Stated by the paper: immune responses are "highly individualistic," making concrete conclusions from small patient cohorts difficult; mechanistic insights into how responses occur at cellular or molecular levels are missing; immunosuppressive regimens are rarely reported in animal studies and inadequately documented in human studies, and no systematic comparative studies of corticosteroids exist.
- Evident from the text: as a narrative review without a described search strategy, selection of cited studies may be non-exhaustive; several cited findings rest on very small samples (e.g., 3 serum samples, 3 patients, 8 patients), and the review itself notes that long-term immune-response data after Cas9 delivery in patients are not yet available.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
16 Valid · 6 Not valid · 96 Not checked · 40 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, a study conducted on 41 non-human primates (NHP) revealed that the highest level of antibodies was against AAV8 and AAV9 [30].”
§ Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy > 2. Pre-Existing Immunity
What the sources say
- Supportedcites [30] Ail, D.; Ren, D.; Brazhnikova, E.; Nouvel-Jaillard, C.; Bertin, S.; Mirashrafi, S.B.; Fisson, S.; Dalkara, D. Systemic and Local Immune Responses to Intraocular AAV Vector Administration in Non-Human Primates. Mol. Ther.-Methods Clin. Dev. 2022, 24, 306-316. [CrossRef] source
The Results section (‘Seroprevalence of antibodies against frequently used AAV serotypes in NHP population’) reports testing 41 NHPs and finding the highest antibody levels against AAV8, followed by AAV9, among the four serotypes tested. The claim accurately identifies the two highest, though AAV8 levels were higher than AAV9 levels. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This study also showed that the antibodies' levels were higher in serum than in vitreous liquid [26].”
§ Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy > 2. Pre-Existing Immunity
What the sources say
- Supportedcites [26] Toral, M.A.; Charlesworth, C.T.; Ng, B.; Chemudupati, T.; Homma, S.; Nakauchi, H.; Bassuk, A.G.; Porteus, M.H.; Mahajan, V.B. Investigation of Cas9 Antibodies in the Human Eye. Nat. Commun. 2022, 13, 1053. [CrossRef] source
The Results section (‘Characterization of human vitreous fluid antibodies’) reports an aggregate vitreous-to-serum antibody concentration ratio of approximately 1:143, with sample-to-sample differences. That directly supports the claim that antibody levels were higher in serum than in vitreous fluid. (LLM, conf=0.94)
plainn = 13- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In humans as well as NHPs, the pre-existing antibodies against AAV5 tend to be lower [28,30].”
§ Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy > 2. Pre-Existing Immunity
What the sources say
- Not checked yetcites [28] Boutin, S.; Monteilhet, V.; Veron, P.; Leborgne, C.; Benveniste, O.; Montus, M.F.; Masurier, C. Prevalence of Serum IgG and Neutralizing Factors against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors. Hum. Gene Ther. 2010, 21, 704-712. [CrossRef] source
- Supportedcites [30] Ail, D.; Ren, D.; Brazhnikova, E.; Nouvel-Jaillard, C.; Bertin, S.; Mirashrafi, S.B.; Fisson, S.; Dalkara, D. Systemic and Local Immune Responses to Intraocular AAV Vector Administration in Non-Human Primates. Mol. Ther.-Methods Clin. Dev. 2022, 24, 306-316. [CrossRef] source
The Discussion states that anti-AAV5 antibody levels were low in all NHP samples tested, as they are in human samples. The Results also report lower anti-AAV5 levels than anti-AAV8 and anti-AAV9 levels in the tested NHPs. (LLM, conf=0.94)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“The results showed that there was a higher expression of innate responserelated genes and IFN-β secretion in groups that received 5 -ppp gRNAs.”
§ Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy > 3. Immune Response to Cas Proteins
What the sources say
- Supportedcites [38] Kim, S.; Koo, T.; Jee, H.G.; Cho, H.Y.; Lee, G.; Lim, D.G.; Shin, H.S.; Kim, J.S. CRISPR RNAs Trigger Innate Immune Responses in Human Cells. Genome Res. 2018, 28, 367-373. [CrossRef] source
In the Results section on primary human T cells, 5′-ppp sgRNA up-regulated OAS2 and DDX58 mRNA in CD4+ T cells, and IFNB1 protein was detected in the supernatant. The same passage says 5′-OH sgRNA induced no detectable immune response compared with the mock control; the Methods identify the IFNB1 assay as measuring protein secreted into the medium. Page numbers are not available in the supplied copy. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“They showed that in primary human and mouse fibroblasts, VLP-mediated base editing could be achieved with more than 95% efficiency.”
§ Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy > 6. Immune Response to Non-Viral Vectors
What the sources say
- Supportedcites [83] Banskota, S.; Raguram, A.; Suh, S.; Du, S.W.; Davis, J.R.; Choi, E.H.; Wang, X.; Nielsen, S.C.; Newby, G.A.; Randolph, P.B.; et al. Engineered Virus-like Particles for Efficient in Vivo Delivery of Therapeutic Proteins. Cell 2022, 185, 250-265.e16. [CrossRef] source
The Results section 'v4 BE-eVLPs efficiently edit primary human and mouse cells' states that after transducing primary human patient-derived fibroblasts homozygous for COL7A1(R185X) with v4 BE-eVLPs, >95% editing was observed at the target adenine, and that >95% correction of the Idua(W392X) mutation was seen in primary mouse fibroblasts (Figure 4A/4B). The same passage concludes that v4 BE-eVLPs can achieve base editing levels in primary human and mouse fibroblasts approaching 100%, matching the paraphrase. (LLM, conf=0.93)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
73 more claims · 8 with their cited sources checked
Create a free account to see all 158 claims and to verify the 105 references still open.
- It may state two separate claims as one. 72
- Probably not a substantial claim. 11
- The quote only partly states this claim. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immunogenicity against the viral vector that limits gene therapy efficacy is a major concern.4,21,25,26,141 and is one of the biggest exclusion criteria in clinical trials.14,26”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several studies have observed antidrug antibody responses and inflammation in the eyes due to immune cell infiltration following retinal gene therapy.21,23–27”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [25]
In the citing paper
“In addition to neutralizing antibodies, cell based immune responses have often been observed at higher doses (above 1 × 1011 vg) in many ocular gene therapy trials.25,26”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy > 1. Introduction
“Adenoviruses (Ads), which can reach a packaging capacity of 37 kb [12].”
§ Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy > 5. Immune Response to Other Viral Vectors
“Adenoviruses (Ads) can offer one of the largest capacities for delivering transgenes of up to 36 kb [12].”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy > 3. Immune Response to Cas Proteins
“a CRISPR-Cas9-based gene therapy to correct this mutation called EDIT-101 was evaluated in a pre-clinical study.”
§ Immune Responses to Gene Editing by Viral and Non-Viral Delivery Vectors Used in Retinal Gene Therapy > 3. Immune Response to Cas Proteins
“The promising results of this pre-clinical study gave rise to a gene-editing product named EDIT-10”
Citations
Cites
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947 · cited 1×
“CRISPR-associated proteins (Cas) are present in most archaea and bacteria as adaptive immune systems [31] and provide sequence-specific resistance against phages [32].”
BackgroundHigh-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
An updated evolutionary classification of CRISPR–Cas systems
Makarova, K. S., Wolf, Y. I., Alkhnbashi, O. S., Costa, F., Shah, S. A., Saunders, S. J., Barrangou, R., Brouns, S. J. J., Charpentier, E., Haft, D. H., et al. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3569 · Cited by 2,480 · cited 1×
“CRISPR-associated proteins (Cas) are present in most archaea and bacteria as adaptive immune systems [31] and provide sequence-specific resistance against phages [32].”
BackgroundRussell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952 · cited 1×
“In a LCA clinical trial (NCT00999609, Phase 3), mild inflammation was observed in 2 of the 21 patients who received the RPE65 gene packaged in AAV2 vectors [45].”
BackgroundAdeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362 · cited 1×
“AAV is the most widely used vector for ocular gene therapy due to its non-pathogenic nature [42], transduction efficiency and ability to transduce a wide variety of cell types [43].”
BackgroundIdentification of preexisting adaptive immunity to Cas9 proteins in humans
Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Bode, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0326-x · Cited by 1,093
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Clinical use of lentiviral vectors
Milone, M. C., & O’Doherty, U. (2018) · Leukemia · doi:10.1038/s41375-018-0106-0 · Cited by 930 · cited 1×
“Additionally, they are genome-integrating, and their integration can at times occur at an oncogenic locus [13].”
Background
Cited by
Advanced Strategies for Overcoming Endosomal/Lysosomal Barrier in Nanodrug Delivery
Qiu, C., Xia, F., Zhang, J., Shi, Q., Meng, Y., Wang, C., Pang, H., Gu, L., Xu, C., Guo, Q., et al. (2023) · Research · doi:10.34133/research.0148 · Cited by 224
“Owing to their natural endosomal escape property, viruses may act as potential vectors to deliver drugs; however, their high toxicity and immunogenicity hinder their application in clinical settings [132].”
BackgroundImmunogenicity of CRISPR therapeutics—Critical considerations for clinical translation
Ewaisha, R., & Anderson, K. S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1138596 · Cited by 165
“One example of these immune-privileged sites is the eye, where inflammatory responses are limited to avoid impact on vision (Benati et al., 2020; Ren et al., 2022).”
BackgroundGene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Neumann, E. N., Bertozzi, T. M., Wu, E., Serack, F. E., Harvey, J. W., Brauer, P. P., Pirtle, C. P., Coffey, A. A., Howard, M., Kamath, N., et al. (2024) · Science · doi:10.1126/science.ado7082 · Cited by 135
“Moreover, given that AAV genomes form concatenated epi-somes that chronically express the transgene, the bacterial enzyme Cas9 is likely to become antigenic over time ( 34 , 35 ); a large proportion of the human population already has an immune memory of it ( 36 ).”
Cheng, L., Zhu, Y., Ma, J., Aggarwal, A., Toh, W. H., Shin, C., Sangpachatanaruk, W., Weng, G. W., Kumar, R., & Mao, H. (2024) · ACS Nano · doi:10.1021/acsnano.4c07615 · Cited by 80
Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?
Ail, D., Malki, H., Zin, E. A., & Dalkara, D. (2023) · The Application of Clinical Genetics · doi:10.2147/tacg.s383453 · Cited by 40
“These pre-existing BAbs and NAbs are serotype, species, age and population specific.(44) The highest seroprevalence in the human population was for anti-AAV2 antibodies, while antiAAV8 was the lowest.”
BackgroundSelf-citationStrategies for targeted gene delivery using lipid nanoparticles and cell-derived nanovesicles
Lee, D. S., Amirthalingam, S., Lee, C., Rajendran, A. K., Ahn, Y.-H., & Hwang, N. S.-Y. (2023) · Nanoscale Advances · doi:10.1039/d3na00198a · Cited by 40
Toward low-cost gene therapy: mRNA-based therapeutics for treatment of inherited retinal diseases
Antas, P., Carvalho, C., Cabral-Teixeira, J., de Lemos, L., & Seabra, M. C. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.11.009 · Cited by 36
Nanoparticles and cytokine response
Nasrullah, M., Sundaram, D. N. M., Claerhout, J., Ha, K., Demirkaya, E., & Uludağ, H. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1243651 · Cited by 36
“Non-viral vectors such as chitosan showed inflammation and retinal damage while PCEP (poly(((cholesteryloxocarbonylamidoethyl) methylbis(ethylene) ammonium iodide) ethyl phosphate)) showed 15% retinal degeneration in rabbits (Ren et al., 2022).”
BackgroundInfluentialNext generation therapeutics for retinal neurodegenerative diseases
Appell, M. B., Pejavar, J., Pasupathy, A., Rompicharla, S. V. K., Abbasi, S., Malmberg, K., Kolodziejski, P., & Ensign, L. M. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.063 · Cited by 34
Garg, P., Singhal, G., Pareek, S., Kulkarni, P., Horne, D., Nath, A., Salgia, R., & Singhal, S. S. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189233 · Cited by 45
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
The Future of Nanomaterials Tackling the Challenge of Delivering Nucleic Acids to the Retina
Hurst, J., Adams, F., & Schnichels, S. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202407173 · Cited by 24
Pig models in retinal research and retinal disease
McCall, M. A. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041296 · Cited by 21
Li, W., Vanluchene, H., Raes, L., Peynshaert, K., Veys, L., Hernández, S. G., Lombaerde, E. D., Geest, B. G. D., Sanders, N. N., Moons, L., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114027 · Cited by 21
Neutralizing Antibodies: Role in Immune Response and Viral Vector Based Gene Therapy
Tsaregorodtseva, T. S., Gubaidullina, A. A., Kayumova, B. R., Shaimardanova, A. A., Issa, S. S., Solovyeva, V. V., Sufianov, A. A., Суфианова, Г. З., & Rizvanov, A. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115224 · Cited by 20
“This study also showed that nAb levels were higher in serum compared to vitreous fluid [172].”
Jain, S., Bhushan, B., Mishra, A. K., & Singh, R. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106413 · Cited by 20
A Comparative Analysis of Models for AAV-Mediated Gene Therapy for Inherited Retinal Diseases
Alsalloum, A., Gornostal, E. A., Mingaleva, N., Pavlov, R. E., Kuznetsova, E., Antonova, E., Nadzhafova, A., Колотова, Д. Е., Кадышев, В. В., Mityaeva, O. N., et al. (2024) · Cells · doi:10.3390/cells13201706 · Cited by 20
“In particular, mouse systems frequently exhibit a heightened immune response to viral vectors utilized in gene therapy applications [19].”
BackgroundModern Strategies of Drug Therapy: Multi-Target Drug Delivery, Bioimaging, Diagnostics
Fedorova, O. V., Ovchinnikova, I. G., Rusinov, G. L., Avdeeva, V. V., Zhdanov, А. P., Zhizhin, K. Y., Kuznetsov, N. T., Zakharova, L. Y., Kuznetsova, D. A., Razuvayeva, Y. S., et al. (2025) · Russian Journal of General Chemistry · doi:10.1134/s1070363225606726 · Cited by 18
Fischer, A., Ehrlich, A., Plotkin, Y., Ouyang, Y., Asulin, K., Konstantinos, I., Fan, C., Nahmias, Y., & Willner, I. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202311590 · Cited by 17
Retinal Imaging Findings in Inherited Retinal Diseases
Corradetti, G., Verma, A., Tojjar, J., Almidani, L., Oncel, D., Emamverdi, M., Bradley, A., Lindenberg, S., Nittala, M. G., & Sadda, S. R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072079 · Cited by 16
Immune responses in retinal gene therapy: challenges, mechanisms, and future strategies
Ma, Y., & Shen, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1664968 · Cited by 15
“After activation, CD8 + cytotoxic T lymphocytes (CTLs) proliferate and differentiate, releasing perforins and granzymes to induce apoptosis and kill infected cells (58).”
Advancing Precision Medicine: Recent Innovations in Gene Editing Technologies
Abhijith, K., & Thangavel, S. (2025) · Advanced Science · doi:10.1002/advs.202410237 · Cited by 15
Ocular Safety and Toxicology of Subretinal Gene Therapy With rAAV.hPDE6A in Nonhuman Primates
Seitz, I. P., Wozar, F., Ochakovski, G. A., Reichel, F. F., Korte, S., Korbmacher, B., Wilhelm, B., Süßkind, D., Bartz‐Schmidt, K. U., Fischer, M. D., et al. (2025) · Translational Vision Science & Technology · doi:10.1167/tvst.14.1.29 · Cited by 12
Promising RNA-based therapies for viral infections, genetic disorders, and cancer
Musa, D. A., Raji, M. O., Sikiru, A. B., Aremu, H. K., & Aigboeghian, E. A. (2024) · Academia molecular biology and genomics. · doi:10.20935/acadmolbiogen7329 · Cited by 11
Gene therapy for retinal diseases: From genetics to treatment
Khaparde, A., Mathias, G. P., Poornachandra, B., Thirumalesh, M. B., Shetty, R., & Ghosh, A. (2024) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_2902_23 · Cited by 10
“[84] In a previous report, co‑transfection of a recombinant ABCA4 with a plasmid that expresses murine leukemia virus proteins gag and pol in HEK293T cells, formed virus‑like particles (VLPs lacking viral RNA) enriched with the recombinant ABCA4.”
BackgroundПечникова, Н. А., Poimenidou, M., Iliadis, I., Zafeiriou-Chatziefraimidou, M., Iaremenko, A. V., Yaremenko, T. V., Domvri, K., & Yaremenko, A. V. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030898 · Cited by 8
Tackling visual impairment: emerging avenues in ophthalmology
Lin, F., Su, Y., Zhao, C., Akter, F., Yao, S., Huang, S., Shao, X., & Yao, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1567159 · Cited by 10
“The immune response to viral vectors poses a risk of inflammation and could reduce the effectiveness of the therapy (18, 19).”
Fischer, A., Ehrlich, A., Plotkin, Y., Ouyang, Y., Asulin, K., Ioannidis, K., Fan, C., Nahmias, Y., & Willner, I. (2023) · Angewandte Chemie · doi:10.1002/ange.202311590 · Cited by 6
Leferman, C.-E., & Ciubotaru, A. D. (2025) · Journal of Medicine and Life · doi:10.25122/jml-2025-0180 · Cited by 5
“These data demonstrate that a single gene-transfer event can yield multi-year therapeutic activity within the ocu - lar compartment [51-53].”
Nonviral DNA delivery’s recent successes and final hurdles
Tiwari, S., Patel, M. N., & Brenner, J. S. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103734 · Cited by 4
Ross, M., Sade, K., Obolensky, A., Averbukh, E., Desrosiers, M., Rosov, A., Dvir, H., Gootwine, E., Banin, E., Dalkara, D., et al. (2024) · Gene Therapy · doi:10.1038/s41434-024-00495-5 · Cited by 3
Self-citationBiologics-device combinations: Enabling prolonged therapies in the posterior segment ocular disease
Zhu, S., Zhang, J., Jiang, X., Peng, C., Liu, H., & Qian, F. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115773 · Cited by 3
Crossing the blood-brain barrier: The therapeutic potential of lncRNAs in neurosurgery
Khazeni, S., & Mousavi, S. Y. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.110487 · Cited by 3
Sun, L., Rao, S., Kerim, K., Li, H., Li, H., Zhao, S., Shen, P., & Sun, W. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116262 · Cited by 3
Jang, Y., Lee, S., Cho, Y., & Seong, H. (2026) · Small Structures · doi:10.1002/sstr.202500767 · Cited by 2
The future of pediatric gene therapy: CRISPR-Cas9, AI, and personalized medicine
Pan, Y., Ding, J., Wang, W., Xu, D., Fan, J., & Zhang, W. (2026) · Pediatric Research · doi:10.1038/s41390-026-05270-3 · Cited by 2
Hamidi, A. L. (2023) · Engineering materials · doi:10.1007/978-981-99-6698-1_21 · Cited by 2
Gene-edited cells: novel allogeneic gene/cell therapy for epidermolysis bullosa
Gila, F., Alamdari-Palangi, V., Rafiee, M., Jokar, A., Ehtiati, S., Dianatinasab, A., Khatami, S. H., Taheri‐Anganeh, M., Movahedpour, A., & Fallahi, J. (2024) · Journal of Applied Genetics · doi:10.1007/s13353-024-00839-2 · Cited by 2
“Additionally, the immune response to the viral vectors used for gene delivery can pose a limitation, potentially leading to inflammation or immune rejection of the corrected cells (Ren et al. 2022; Wu and Ertl 2009).”
Castro, B. F. M., Lugin, M. L., Guerra, M. C. A., Dias, M. F., Lee, R. T., Silva‐Cunha, A., Kwon, Y. J., & Fialho, S. L. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-02001-9 · Cited by 1
“On the other hand, non-viral gene delivery approaches including polymeric or magnetic nanoparticles and lipid-based plat - forms allow enhanced cargo flexibility, reduced immunoge - nicity, low manufacturing costs, and easy scalability [ 8–10].”
Ren, D., Chauveau, G. A., Cabon, E., Vendomèle, J., Vignal‐Clermont, C., Saliba, H., Ail, D., Dalkara, D., & Fisson, S. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101443 · Cited by 1
Self-citationRen, D., Chauveau, G. A., Vendomèle, J., Cabon, E., PINEIRO, A., Vignal‐Clermont, C., Saliba, H., Ronzitti, G., Galy, A. H. M., Dalkara, D., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.199587 · Cited by 1
“Nevertheless, immune responses triggered by AAV capsids and transgene products remain a concern, as they are observed both peripherally and locally in preclinical and clinical studies, and they are generally considered as factors that can negatively affect the effectiveness of gene therapy (38–40).”
Self-citationPulman, J., Ren, D., Visticot, L., Malki, H., Yao, Y., Cian, A. D., Ail, D., Concordet, J., Dalkara, D., & Fisson, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.11.693665 · Cited by 2
“Indeed, viral vectors, such as adeno-associated virus (AAV), can induce local inflammation and T-cell infiltration into the retina after intraocular delivery ( 10 – 13 ) , adding to concerns about Cas9-induced inflammation ( 5 , 9 , 10 , 14 ) .”
Self-citationDRUG DELIVERY SYSTEMS USED FOR BIOLOGICAL PRODUCTS
Saka, O. M. (2023) · Journal of Research in Pharmacy · doi:10.29228/jrp.501
Uludağ, H., Wang, Y., Vrana, N. E., Tamerler, C., Kothapalli, C. R., & Vasudev, M. C. (2024) · Frontiers research topics · doi:10.3389/978-2-8325-4414-3
Updates on Gene Therapy for Neovascular Age-related Macular Degeneration: A Review
Sharma, A., & Kumar, N. (2024) · EyeQuest · doi:10.4103/equest.equest_25_24
Role of hydrogel for the diagnosis and treatment of eye melanoma
De, A., Chakma, M., Singh, K., Singh, S., & Park, Y. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27541-8.00003-1
Ather, N., & Bint-e-Shahzad, W. (2025) · Pedagogy and Psychology of Sport · doi:10.12775/pps.2025.27.66859
Long, Y., Jia, Q., Zhang, W., Qin, H., & Yao, K. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5723
“Multiple clinical trials for Leber congenital Amaurosis, including NcT00999609, NcT02781480, NcT00749957 and NcT00643747, have similarly reported ocular immune‑related AEs, such as inflam‑ mation, transient increases in AAV neutralizing antibodies and AAV capsid‑specific T cell responses (219).”
Gene therapy for diabetic retinopathy
Capobianco, M., Nicolosi, S. G., Cappellani, F., Khouyyi, M., D’Esposito, F., Gagliano, C., & Zeppieri, M. (2026) · World Journal of Clinical Cases · doi:10.12998/wjcc.v14.i11.119413
Gene therapy development for retinal diseases
Reichel, F. F., Bellingrath, J.-S., Király, P., & FISCHER, M. D. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-22212-2.00016-1
Applications of CRISPR-Cas9 Gene Editing Technology in Food Allergy Therapy: A Comprehensive Review
Khalil, A. M. (2026) · Recent Progress in Science and Engineering · doi:10.21926/rpse.2602009
Zeng, N., Jiang, L., Zhang, Y., Liu, J., Zhang, Q., Liao, L., & Hu, Q. (2026) · Molecular Medicine Reports · doi:10.3892/mmr.2026.13969
Clinical translation of CRISPR-Cas9 therapeutics in cancer and inherited genetic disorders
Bashir, K., Vasudev, P., Chhetri, V., Dubhashi, D. P., Teli, Y. G., Biswas, R., Ramaiah, S., & Anbarasu, A. (2026) · Frontiers in Genome Editing · doi:10.3389/fgeed.2026.1868779
“…carriers, and virus-like particles, may provide opportunities to simplify manufacturing and reduce dependence on integrating viral vectors (Ren et al., 2022); however, tissue-specific delivery, biodistribution, immunogenicity, and reproducible therapeutic exposure remain important…”
Pan, C., Zuo, N., Wu, C., & Liu, X. (2026) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2026.119153
Mohiuddin, M., & Ahsan, M. A. M. (2026) · Health Science Reports · doi:10.1002/hsr2.73308
“Gene knockout: Disrupt genes that cause drug resistance (e.g., efflux pumps), or inhibit repair pathways [34–36].”
Metadata
- Authors
- Ren, D., Fisson, S., Dalkara, D., & Ail, D.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Ail, Divya
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-09-19
- Volume
- 14
- Issue
- 9
- Pages
- 1973
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9502120
- OpenAlex
- W4296794285
- Semantic Scholar
- d4e1e7cffb88ed6e29f4da12069d83ddea75f0f0
- Cited by
- 52
- References
- 115
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 14 · 2023: 13
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- ERC Starting Grant (REGENETHER 639888, ANR-10-LABX-65, ANR-18-IAHU-01)
- Institut National de la Santé et de la Recherche Médicale (INSERM) (REGENETHER 639888, ANR-10-LABX-65, ANR-18-IAHU-01)
- Sorbonne Université (REGENETHER 639888, ANR-10-LABX-65, ANR-18-IAHU-01)
- The Foundation Fighting Blindness (REGENETHER 639888, ANR-10-LABX-65, ANR-18-IAHU-01)
- Agence National de Recherche (ANR) RHU Light4Deaf (REGENETHER 639888, ANR-10-LABX-65, ANR-18-IAHU-01)
- *LabEx LIFESENSES (REGENETHER 639888, ANR-10-LABX-65, ANR-18-IAHU-01)
- *IHU FOReSIGHT (REGENETHER 639888, ANR-10-LABX-65, ANR-18-IAHU-01)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- retinal gene therapy, CRISPR/Cas9 genome editing, immune response, viral vectors, non-viral vectors, inherited retinal disease, ocular inflammation, immune privilege, innate immunity, adaptive immunity, pre-existing immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.